Already have an account? Sign in.
Excitement Builds for Skye Bioscience's Potential Weight Loss Game-Changer
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
RBC Capital downgrades Starbucks to Sector Perform from Outperform, citing higher labor costs, smaller savings, and elevated growth expectations near peak valuation.
Argus downgrades Duolingo stock from Buy to Hold, citing pressure on revenue from focus on daily user growth via chess, math, and music expansions.
TD Cowen upgrades Grail to Buy from Hold with $65 target after 60% selloff. Analyst sees attractive entry in multi-cancer detection despite NHS study miss.